Research progress in cyclopeptide: anticancer mechanisms and targeted delivery systems
DOI:
https://doi.org/10.54097/hbm13q78Keywords:
Cyclopeptide, Breast cancer, Structure, Targeted delivery.Abstract
Breast cancer is a serious health concern for women globally. Traditional therapies including surgery chemotherapy, radiotherapy and endocrine therapy can control breast cancer effectively, but their effectiveness is often hindered by drug resistance and side effects. Cyclopeptides, a class of biomolecules with a closed-loop structure, present a promising alternative due to their stability potency and specificity.This review delves into the mechanisms of cyclopeptides in breast cancer treatment, evaluating their effectiveness and challenges. And also discusses the studies concerning the anti-cancer activities and delivery systems of cyclopeptides such as cyclosporin A and deoxybouvardin (RA-V). Innovations in nanotechnology and targeted delivery systems further optimize cyclopeptide therapies, enhancing their efficiency and reducing side effects. Research suggests that cyclopeptides can effectively halt the proliferation and metastasis of breast cancer cells. They achieve this through various mechanisms, such as inhibiting key cancer pathways, inducing tumor cell apoptosis, and enhancing drug efficacy via targeted delivery systems. This review highlights the application of cyclopeptides in breast cancer treatment and discusses the targeted delivery technologies of cyclopeptides.
Downloads
References
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries .CA Cancer J Clin. 2024;74(3): 229-263.
Wu, Q.; Siddharth, S.; Sharma, D. Triple negative breast cancer: a mountain yet to be scaled despite the triumphs. Cancers 2021, 13, 3697.
Costa L, Sousa E, Fernandes C. Cyclic peptides in pipeline: what future for these great molecules? Pharmaceuticals (Basel). 2023 Jul 12;16(7):996.
Sharma K, Sharma KK, Sharma A, Jain R. Peptide-based drug discovery: current status and recent advances. Drug Discov Today. 2023 Feb;28(2):103464.
Hayes HC, Luk LYP, Tsai YH. Approaches for peptide and protein cyclisation. Org Biomol Chem. 2021 May 12;19(18):3983-4001.
Zhang H, Chen S. Cyclic peptide drugs approved in the last two decades (2001-2021). RSC Chem Biol. 2021 Nov 5;3(1):18-31.
Craik DJ. Chemistry. Seamless proteins tie up their loose ends. Science. 2006 Mar 17;311(5767):1563-4.
Yang H, Li S, Li W, Yang Y, Zhang Y, Zhang S, Hao Y, Cao W, Xu F, Wang H, Du G, Wang J. Actinomycin D synergizes with doxorubicin in triple-negative breast cancer by inducing P53-dependent cell apoptosis. Carcinogenesis. 2024 Apr 12;45(4):262-273.
Jiang K, He B, Lai L, Chen Q, Liu Y, Guo Q, Wang Q. Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2. Int J Mol Med. 2012 Aug;30(2):302-8.
Fang XY, Chen W, Fan JT, Song R, Wang L, Gu YH, Zeng GZ, Shen Y, Wu XF, Tan NH, Xu Q, Sun Y. Plant cyclopeptide RA-V kills human breast cancer cells by inducing mitochondria-mediated apoptosis through blocking PDK1-AKT interaction. Toxicol Appl Pharmacol. 2013 Feb 15;267(1):95-103.
Myrberg H, Zhang L, Mäe M, Langel U. Design of a tumor-homing cell-penetrating peptide. Bioconjug Chem. 2008 Jan;19(1):70-5.
Balachandran P, Ibrahim MA, Zhang J, Wang M, Pasco DS, Muhammad I. Crosstalk of cancer signaling pathways by cyclic hexapeptides and anthraquinones from rubia cordifolia. Molecules. 2021 Jan 31;26(3):735.
Leung HW, Wang Z, Yue GG, Zhao SM, Lee JK, Fung KP, Leung PC, Lau CB, Tan NH. Cyclopeptide RA-V inhibits cell adhesion and invasion in both estrogen receptor positive and negative breast cancer cells via PI3K/AKT and NF-κB signaling pathways. Biochim Biophys Acta. 2015 Aug;1853(8):1827-40.
Xiong S, Mu T, Wang G, Jiang X. Mitochondria-mediated apoptosis in mammals. Protein Cell. 2014 Oct;5(10):737-49.
Siboni RB, Nakamori M, Wagner SD, Struck AJ, Coonrod LA, Harriott SA, Cass DM, Tanner MK, Berglund JA. Actinomycin D specifically reduces expanded CUG repeat RNA in myotonic dystrophy models. Cell Rep. 2015 Dec 22;13(11):2386-2394.
Das T, Nair RR, Green R, Padhee S, Howell M, Banerjee J, Mohapatra SS, Mohapatra S. Actinomycin D down-regulates SOX2 expression and induces death in breast cancer stem cells. Anticancer Res. 2017 Apr;37(4):1655-1663.
Mauro-Lizcano M, Sotgia F, Lisanti MP. SOX2-high cancer cells exhibit an aggressive phenotype, with increases in stemness, proliferation and invasion, as well as higher metabolic activity and ATP production. Aging (Albany NY). 2022 Dec 22;14(24):9877.
Lin S, Zhang C, Liu F, Ma J, Jia F, Han Z, Xie W, Li X. Actinomycin V Inhibits Migration and Invasion via Suppressing Snail/Slug-Mediated Epithelial-Mesenchymal Transition Progression in Human Breast Cancer MDA-MB-231 Cells In Vitro. Mar Drugs. 2019 May 24;17(5):305.
Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol. 1999 Nov 1;147(3):631-44.
Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF, Ruoslahti E. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 2009 Dec 8;16(6):510-20.
He S, Fang Y, Wu M, Zhang P, Gao F, Hu H, Sheng C, Dong G. Enhanced tumor targeting and penetration of proteolysis-targeting chimeras through iRGD peptide conjugation: a strategy for precise protein degradation in breast cancer. J Med Chem. 2023 Dec 28;66(24):16828-16842.
Wang X, Zhao Y, Yan M, Liang X, Zhao N, Lu T. iRGD mediated pH-responsive mesoporous silica enhances drug accumulation in tumors. Eur J Pharm Sci. 2024 Apr 1;195:106725.
Qian J, Zhou S, Lin P, Lei J, Zheng S, Xu W, Wang Y, Gao Z, Yang J. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis. Drug Dev Res. 2023 Jun;84(4):654-670.
Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med. 2002 Jul;8(7):751-5.
Song N, Zhao L, Zhu M, Zhao J. 99mTc-labeled LyP-1 for SPECT imaging of triple negative breast cancer. Contrast Media Mol Imaging. 2019 Sep 25;2019:9502712.
Xu W, Yang Y, Hu Z, Head M, Mangold KA, Sullivan M, Wang E, Saha P, Gulukota K, Helseth DL, Guise T, Prabhkar BS, Kaul K, Schreiber H, Seth P. LyP-1-modified oncolytic adenoviruses targeting transforming growth factor β inhibit tumor growth and metastases and augment immune checkpoint inhibitor therapy in breast cancer mouse models. Hum Gene Ther. 2020 Aug;31(15-16):863-880.
Zhang Y, Ouyang Z, Zhan M, Yang R, Gao Y, Li L, Guo R, Shi X, Cao X. An intelligent vascular disrupting dendritic nanodevice incorporating copper sulfide nanoparticles for immune modulation-mediated combination tumor therapy. Small. 2023 Sep;19(39):e2301914.
Corrie.Cytotoxic chemotherapy: clinical aspects.Medicine,Volume 36, Issue 1,2008,Pages 24-28,ISSN 1357-3039.
Timur SS, Yöyen-Ermiş D, Esendağlı G, Yonat S, Horzum U, Esendağlı G, Gürsoy RN. Efficacy of a novel LyP-1-containing self-microemulsifying drug delivery system (SMEDDS) for active targeting to breast cancer. Eur J Pharm Biopharm. 2019 Mar; 136:138-146.
Park SE, Sajid MI, Parang K, Tiwari RK. Cyclic Cell-Penetrating Peptides as Efficient Intracellular Drug Delivery Tools. Mol Pharm. 2019 Sep 3;16(9):3727-3743.
Park SE, El-Sayed NS, Shamloo K, Lohan S, Kumar S, Sajid MI, Tiwari RK. Targeted delivery of cabazitaxel using cyclic cell-penetrating peptide and biomarkers of extracellular matrix for prostate and breast cancer therapy. Bioconjug Chem.2021 Aug 18;32(8):1898-1914.
Qiao ZY , Zhang D , Hou CY , Zhao SM , Liu Y , Gao YJ , Tan NH , Wang H . A pH-responsive natural cyclopeptide RA-V drug formulation for improved breast cancer therapy. J Mater Chem B. 2015 Jun 14;3(22):4514-4523.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
